Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Rapid symptom improvement and sustained 4-week benefits distinguish Spravato monotherapy in treatment-resistant depression, with significant MADRS score reductions versus placebo.
Psychiatry February 5th 2025
MedCentral
Suzetrigine, a newly approved NaV1.8 inhibitor, offers a promising non-opioid alternative for managing moderate-to-severe acute pain, backed by robust clinical trial data.
Anesthesiology February 3rd 2025
Oncology Learning Network
The Trop-2-directed antibody-drug conjugate demonstrated a 2.3-month improvement in progression-free survival compared to standard chemotherapy options, offering a new treatment pathway for patients with limited options.
Oncology, Medical January 21st 2025
Nearly half of clinical trial participants achieved such significant improvements that their OSA symptoms were effectively resolved, marking a significant advancement in treating this complex disorder.
Endocrinology, Diabetes, Metabolism January 8th 2025
Oncology News Central (ONC)
The inavolisib-based regimen more than doubled progression-free survival in PIK3CA-mutated breast cancers, offering a new standard of care for this challenging patient population.
Oncology, Medical October 21st 2024
In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.
Family Medicine/General Practice October 16th 2024